10002852 J Clin Psychiatry / Document Archive

Psychiatrist.com Home    Keyword Search

Close [X]

Search Our Sites

Enter search terms below (keywords, titles, authors, or subjects). Then select a category to search and press the Search button. All words are assumed to be required. To search for an exact phrase, put it in quotes. To exclude a term, precede it with a minus sign (-).

Keyword search:

Choose a category:

Choosing the appropriate category will greatly improve your chances of finding the best match.

All files at our sites: J Clin Psychiatry, Primary Care Companion, CME Institute, and MedFair

Search materials from our journals:

Abstracts from The Journal of Clinical Psychiatry, 1996–present, both regular issues and supplements

PDFs of the full text of The Journal of Clinical Psychiatry, 1996–present, both regular issues and supplements (Net Society Platinum [paid subscribers])

PDFs of the full text of The Primary Care Companion to The Journal of Clinical Psychiatry, 1999–present

Search CME offerings:

CME Institute, including CME from journals , supplements, and Web activities for instant CME credit (Net Society Gold [registered users]); also includes information about our CME program

CME activities from regular issues of The Journal of Clinical Psychiatry (Net Society Gold [registered users])

CME Supplements from The Journal of Clinical Psychiatry (Net Society Gold [registered users])


The article you requested is

Relapse Rates in Patients With Schizophrenia Receiving Aripiprazole in Comparison With Other Atypical Antipsychotics.

J Clin Psychiatry 2006;67:1942-1947
Copyright 2006 Physicians Postgraduate Press, Inc.

To view this item, select one of the options below.

    1. Purchase this PDF for $40
      If you are not a paid subscriber, you may purchase the PDF.
      (You'll need the free Adobe Acrobat Reader.)
    2. Subscribe
      Receive immediate full-text access to JCP. You can subscribe to JCP print + online for $166 individual.
      JCP's 75th AnniversaryCelebrate!
      Celebrate JCP's 75th Anniversary with a special online-only subscription price of $75.
    1. Activate
      If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
    2. Sign in
      As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
  1. Did you forget your password?

Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email


Objective: Aripiprazole is the first of a new generation of antipsychotics that possesses a unique mechanism of action as a partial dopamine agonist. After the release of aripiprazole, case reports appeared conveying an acute psychosis/agitation reaction occurring after the initiation of treatment, most specifically after patients were switched from a previous antipsychotic to aripiprazole. The primary objective of this study was to compare relapse rates among patients with schizophrenia who were switched to aripiprazole with those who switched to a second-generation antipsychotic (SGA) from another antipsychotic.

Method: The design was a retrospective cohort study based on Kansas Medicaid enrollees with an ICD-9-CM diagnosis code for schizophrenia during calendar year 2002 who switched antipsychotic agents. Six-month psychiatric relapse rates, defined as hospitalization for a psychiatric event, were compared between those subjects who switched to aripiprazole and those who switched to another SGA. Time to relapse was modeled using Cox proportional hazards, adjusting for demographic characteristics, major comorbid conditions, and prior psychiatric-related health care use.

Results: Four hundred forty-four aripiprazole and 521 SGA switchers were comparable with respect to gender, race, comorbidities, and health care utilization, though the aripiprazole group was 4.5 years younger. Twenty percent of aripiprazole patients and 19.4% of patients receiving SGAs were hospitalized 6 months after being switched (relative risk = 0.92; 95% CI = 0.67 to 1.26). Mean times to psychiatric hospitalization for the aripiprazole and SGA groups were 65.7 and 73.8 days, respectively (p > .05). Factors associated with hospitalization were prior psychiatric hospitalizations and comorbid depression, substance abuse, and neurotic, personality, and nonpsychotic mental disorders.

Conclusion: Our study found that rates of relapse and time to relapse with aripiprazole were comparable to other SGAs during a 6-month period. Thus, aripiprazole appears to be an appropriate first-line agent along with the other SGAs.